Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Regulated mRNA Transport02:22

Regulated mRNA Transport

2.8K
2.8K
Regulation of Expression at Multiple Steps01:23

Regulation of Expression at Multiple Steps

875
The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
875
MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
mRNA Stability and Gene Expression02:51

mRNA Stability and Gene Expression

2.8K
2.8K
Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Riboswitches01:56

Riboswitches

8.1K
Riboswitches are non-coding mRNA domains that regulate the transcription and translation of downstream genes without the help of proteins. Riboswitches bind directly to a metabolite and can form unique stem-loop or hairpin structures in response to the amount of the metabolite present. They have two distinct regions – a metabolite-binding aptamer and an expression platform.
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
8.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Dual-targeting macrophage membrane nanosystem enhances radiotherapy-induced antitumor immunity <i>via</i> synergistic nuclear and mitochondrial DNA damage.

Biomaterials science·2026
Same author

Unveiling molecular incomplete response (mIR) <i>via</i> ultra-deep NGS: a novel concept contrasting pathologic complete response (pCR) in occult lymph node micrometastases of non-small cell lung cancer.

Cancer biology & medicine·2026
Same author

From antibiotic impasse to cellular breakthrough: Advances in cell-based and cell-inspired strategies against bacterial infections.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Elastin production by mRNA technology for rejuvenation of aged skin.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Inhibition of protein kinase CK2 remodels the tumor immune microenvironment and sensitizes lung cancer to PD-L1 blockade.

Experimental hematology & oncology·2026
Same author

Comparative analysis of large language models and clinicians in thyroid eye disease using structured questionnaires.

Scientific reports·2026

相关实验视频

Updated: Jun 11, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.1K

针对优化mRNA表达的制药策略

Yingying Shi1, Jiapeng Mao1, Sijie Wang1

  • 1College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang, 310058, PR China.

Biomaterials
|September 29, 2024
PubMed
概括

通过调节蛋白质水平,信使RNA (mRNA) 传递系统对于治疗疾病至关重要. 本综述探讨了非病毒载体策略,以提高mRNA稳定性,输送和治疗疗效.

关键词:
制药战略 制药战略 制药战略稳定的稳定性 稳定的稳定性目标站点积累目标站点积累转换效率的转换效率是什么它们是mRNARNA.

更多相关视频

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

10.0K
In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells
10:07

In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells

Published on: November 13, 2014

24.9K

相关实验视频

Last Updated: Jun 11, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.1K
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

10.0K
In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells
10:07

In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells

Published on: November 13, 2014

24.9K

科学领域:

  • 生物技术和制药科学 生物技术和制药科学
  • 分子医学是分子医学.
  • 药物输送系统 药物输送系统

背景情况:

  • 使者RNA (mRNA) 疗法为治疗与异常蛋白质水平相关的疾病提供了潜力.
  • 有效地将mRNA输送到目标细胞对于治疗成功至关重要.
  • 非病毒载体是安全和稳定的mRNA输送的关键药物战略.

研究的目的:

  • 从制药的角度来看,审查现有的mRNA输送系统.
  • 分析配方和制备技术对非病毒载体的影响.
  • 探索将mRNA与小分子结合的策略,以提高治疗效果.

主要方法:

  • 关于mRNA输送系统的当前文献的综述.
  • 对非病毒载体的配方调整和制备技术的分析.
  • 检查结合mRNA和小分子的协同策略.

主要成果:

  • 配方和制剂显著影响mRNA稳定性,目标积累和转染效率.
  • 非病毒载体具有不同的结构特征和作用模式.
  • 组合策略可以增加mRNA功效并减轻不良影响.

结论:

  • 优化非病毒载体传递对于推进mRNA疗法至关重要.
  • 对协同作用组合的进一步研究有望提高有效性和安全性.
  • 应对mRNA药物开发方面的挑战将为未来的治疗进步打开大门.